# reload+after+2024-01-21 23:45:29.166567
address1§Ole Maaløes Vej 3
address2§Copenhagen N
city§Copenhagen
zip§2200
country§Denmark
phone§45 70 70 29 80
website§https://www.iobiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
fullTimeEmployees§57
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mai-Britt  Zocca Ph.D.', 'age': 55, 'title': 'Founder, President, CEO, Principal Financial Officer & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 733875, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy B. Sullivan M.B.A.', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 391236, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Inge Marie Svane M.D., Ph.D.', 'title': 'Founder & Clinical Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Mads Hald Andersen M.D., Ph.D.', 'title': 'Founder & Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Anders  Ljungqvist', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Per Thor Straten', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Burkavage', 'age': 39, 'title': 'Chief Accounting Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Faulkner M.B.A.', 'title': 'Chief Technical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Devin Whittemore Smith', 'age': 55, 'title': 'Secretary, General Counsel & Chief Compliance Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel G. Mannix Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.514
currency§USD
dateShortInterest§1702598400
forwardEps§-1.67
exchange§NMS
quoteType§EQUITY
shortName§IO Biotech, Inc.
longName§IO Biotech, Inc.
firstTradeDateEpochUtc§1636119000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ea2848e4-aa90-3bf4-82a5-9ce691c6a8c0
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§7.0
targetMeanPrice§9.0
targetMedianPrice§10.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§12.819
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
